Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven P Sedlis

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Thrombosis Research|June 7, 2005
The ratio of ADP- to ATP-ectonucleotidase activity is reduced in patients with coronary artery diseaseMagdi M El-Omar, Naziba Islam, M Johan Broekman, et al.
Journal of the American College of Cardiology|November 3, 2018
Healthy Behavior, Risk Factor Control, and Survival in the COURAGE TrialDavid J Maron, G B John Mancini, Pamela M Hartigan, et al.
Journal of the American College of Cardiology|August 27, 2013
Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)Subroto Acharjee, William E Boden, Pamela M Hartigan, et al.
Journal of the American Heart Association|August 1, 2019
Angina Severity, Mortality, and Healthcare Utilization Among Veterans With Stable AnginaMina Owlia, John A Dodson, Jordan B King, et al.
The American Journal of Cardiology|September 10, 2013
Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial)Steven P Sedlis, Claudine T Jurkovitz, Pamela M Hartigan, et al.
The American Journal of Cardiology|September 28, 2015
Effect of baseline exercise capacity on outcomes in patients with stable coronary heart disease (a post hoc analysis of the clinical outcomes utilizing revascularization and aggressive drug evaluation trial)Santosh K Padala, Mandeep S Sidhu, Pamela M Hartigan, et al.
The New England Journal of Medicine|November 13, 2015
Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart DiseaseSteven P Sedlis, Pamela M Hartigan, Koon K Teo, et al.
The American Journal of Cardiology|August 2, 2022
Comparison of Characteristics and Outcomes of Veterans With Stable Ischemic Heart Disease Enrolled in the COURAGE Trial Versus the Veterans Affairs Clinical Assessment, Reporting, and Tracking ProgramNathaniel R Smilowitz, Evan P Carey, Binita Shah, et al.
The American Journal of Cardiology|December 8, 2009
Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney diseaseSteven P Sedlis, Claudine T Jurkovitz, Pamela M Hartigan, et al.
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable anginaZugui Zhang, Paul Kolm, William E Boden, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Thrombosis Research|June 7, 2005
The ratio of ADP- to ATP-ectonucleotidase activity is reduced in patients with coronary artery diseaseMagdi M El-Omar, Naziba Islam, M Johan Broekman, et al.
Journal of the American College of Cardiology|November 3, 2018
Healthy Behavior, Risk Factor Control, and Survival in the COURAGE TrialDavid J Maron, G B John Mancini, Pamela M Hartigan, et al.
Journal of the American College of Cardiology|August 27, 2013
Low levels of high-density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: A post-hoc analysis from the COURAGE Trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation)Subroto Acharjee, William E Boden, Pamela M Hartigan, et al.
Journal of the American Heart Association|August 1, 2019
Angina Severity, Mortality, and Healthcare Utilization Among Veterans With Stable AnginaMina Owlia, John A Dodson, Jordan B King, et al.
The American Journal of Cardiology|September 10, 2013
Health status and quality of life in patients with stable coronary artery disease and chronic kidney disease treated with optimal medical therapy or percutaneous coronary intervention (post hoc findings from the COURAGE trial)Steven P Sedlis, Claudine T Jurkovitz, Pamela M Hartigan, et al.
The American Journal of Cardiology|September 28, 2015
Effect of baseline exercise capacity on outcomes in patients with stable coronary heart disease (a post hoc analysis of the clinical outcomes utilizing revascularization and aggressive drug evaluation trial)Santosh K Padala, Mandeep S Sidhu, Pamela M Hartigan, et al.
The New England Journal of Medicine|November 13, 2015
Effect of PCI on Long-Term Survival in Patients with Stable Ischemic Heart DiseaseSteven P Sedlis, Pamela M Hartigan, Koon K Teo, et al.
The American Journal of Cardiology|August 2, 2022
Comparison of Characteristics and Outcomes of Veterans With Stable Ischemic Heart Disease Enrolled in the COURAGE Trial Versus the Veterans Affairs Clinical Assessment, Reporting, and Tracking ProgramNathaniel R Smilowitz, Evan P Carey, Binita Shah, et al.
The American Journal of Cardiology|December 8, 2009
Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney diseaseSteven P Sedlis, Claudine T Jurkovitz, Pamela M Hartigan, et al.
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable anginaZugui Zhang, Paul Kolm, William E Boden, et al.
Pageof 7